News Quantified

SCYX – scynexis, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 [Yahoo! Finance]

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

SCYNEXIS granted Nasdaq extension to regain bid price compliance [Seeking Alpha]

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement [Yahoo! Finance]

-7.3%

BEAT

-7.9%

BEAT

-16.0%

BEAT

Form 4 SCYNEXIS INC For: Jan 29 Filed by: Macleod ivor

Form 4 SCYNEXIS INC For: Jan 29 Filed by: Sukenick Scott

Form 4 SCYNEXIS INC For: Jan 29 Filed by: Angulo Gonzalez David

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: FEDERATED HERMES, INC.

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: Avidity Partners Management LP

Top News Gainers

1/8 SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting 18.0%

4/13 Form 8-K SCYNEXIS INC For: Apr 10 13.1%

12/10 SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants 12.2%

9/18 SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) 11.4%

11/12 SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update 9.1%

1/15 SCYNEXIS Inc (NASDAQ: SCYX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 8.1%

5/1 Form S-3 SCYNEXIS INC 7.4%

4/24 Form 8-K SCYNEXIS INC For: Apr 21 7.3%

12/20 Form SC 13G SCYNEXIS INC Filed by: ARMISTICE CAPITAL, LLC 5.9%

2/18 SCYNEXIS Inc (NASDAQ: SCYX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%

Top News Decliners

3/18 SCYNEXIS Inc (NASDAQ: SCYX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -15.4%

7/24 SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study) -13.5%

4/21 SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) -13.5%

11/14 SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States -12.1%

12/9 SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants -11.8%

3/26 SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020 -11.5%

12/20 The CEO, President & Director of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Just Bought 32% More Shares [Yahoo! Finance News] -9.0%

12/11 Form 424B5 SCYNEXIS INC -7.8%

3/11 Form 10-K SCYNEXIS INC For: Dec 31 -7.2%

11/7 SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303) -7.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day